Functionalized Magnetic beads may help reduce high blood pressure, BP associated complications during pregnancy finds a new study.\r\nAccording to new research,\u00a0early laboratory\u00a0tests show that functionalized magnetic beads successfully reduced blood levels of a harmful molecule that is elevated during preeclampsia. Preeclampsia\u00a0is a complication of pregnancy characterized by high blood pressure, BP and kidney dysfunction.\r\n\r\nThe study has appeared in the American Heart Association's journal\u00a0Hypertension.\r\n\r\nPreeclampsia is serious blood pressure (BP) disorder that can affect all of the organs in a woman\u2019s body. A woman has preeclampsia when she has high blood pressure and other signs that her organ systems are not working normally. One of these signs is\u00a0proteinuria.\r\n\r\n\r\n\r\n\r\n\r\n\r\nIt may lead to severe complications for the mother (seizures, stroke, renal failure, liver dysfunction) and the infant (low birth weight, preterm delivery, stillbirth). The condition also increases a woman's risk for cardiovascular disease later in life (stroke and high blood pressure, BP). At present, there's no cure for preeclampsia, and only childbirth can alleviate symptoms.\r\n\r\nResearchers focused on a molecule, called sFlt-1, which is released by the placenta into the woman's bloodstream and rises to high levels during preeclampsia. High levels of sFlt-1 are responsible for blood vessel wall dysfunction, contributing to high blood pressure, BP and for trapping two other important molecules that enhance blood vessel wall function called VEGF and PIGF.\r\n\r\nUsing blood from women with preeclampsia, researchers conducted laboratory tests to see if magnetic beads could essentially drag sFlt-1 out of circulation, therefore freeing up levels of VEGF and PIGF. They found that magnetic beads reduced sFlt-1 by 40% and freed up to two times more PIGF, reducing the sFlt-1\/PlGF ratio by 63 percent.\r\n\r\n"This was a proof of concept study and our approach aims to restore physiologic levels of angiogenic factors," said lead study author Vassilis Tsatsaris, M.D., Ph.D., a professor of obstetrics and gynaecology at Cochin Hospital in Paris. "The reduction of sFlt-1 and the release of angiogenic factors is very significant and promising."\r\n\r\nAngiogenic factors is any of a group of substances present in the circulation - most of which are polypeptides (i.e., angiogenin, fibroblast growth factor, transforming growth factors and some lipids) which help form blood vessels.\r\n\r\nBased on the success of these early findings, Tsatsaris and his colleagues would like to expand their study and repeat these experiments to see if this approach can control preeclampsia and prolong pregnancy while reducing the risks of prematurity for the baby.